VIMKUNYA™ is an FDA- and EMA-approved, single-dose, recombinant chikungunya vaccine for individuals 12+ years, demonstrating high immunogenicity and tolerability. It’s stored refrigerated, shaken before use, and administered IM. Most adverse effects are mild and transient, with rare serious events that require standard post-vaccination monitoring.
VIMKUNYA™ is used to help protect individuals aged 12 years and older against chikungunya virus infection — a mosquito-borne illness that can cause fever, joint pain, fatigue, rash, and long-term arthritis-like symptoms.
It is especially recommended for:
-
Travelers visiting regions where chikungunya outbreaks are common
-
People living in or moving to endemic areas (e.g., parts of Africa, Asia, the Caribbean, Central and South America)
-
Laboratory and field workers who may be exposed to the virus
The vaccine helps the body build immunity without causing the disease and provides a single-dose option for rapid protection.
Mode of action
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus vitae tempor nulla.
-
Seroresponse rate (neutralizing antibodies):
-
12–64 years: ~98% by 3 weeks post-dose
-
≥ 65 years: ~87% Medicines.org.uk+15CDC+15MPR+15
-
-
At 6 months post-vaccination: antibody levels remain high (85% in younger adults; 76% in older adults) CDC+1U.S. Food and Drug Administration+1.
-
Approved through accelerated FDA (Feb 2025) and MHRA/EMA processes, based on immunogenicity data from Phase III (3,500+ participants) Wikipedia+1Vaccine Advisor+1.
-
No real-world effectiveness studies yet—approval based on neutralizing antibody as surrogate endpoint
35
Lorem ipsum dolor sit amet,
50+
Lorem ipsum dolor sit amet,
100%
Lorem ipsum dolor sit amet,
How To Store
-
Refrigerate at 2–8 °C; keep in original carton, protected from light vimkunyahcp.com+15U.S. Food and Drug Administration+15European Commission+15.
-
Do not freeze.
-
After removal, can be stored at room temperature (≤ 25 °C) for up to 2 h (US) or 4 h (EU/UK) before use
Dosage & Administration
0.8 mL (≈ 40 µg VLPs + aluminium adjuvant)
to create a uniform suspension (white, cloudy) before injection
do not give IV, ID, or SC
Contraindications
-
History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine
-
Pregnancy and immune‑compromised individuals: use with caution; protective efficacy may be reduced; monitor closely U.S. Food and Drug AdministrationEuropean Commission.
-
Postpone vaccination during acute severe febrile illnesses
Side Effects
Common (≥10% in ages 12–64):
-
Injection-site pain (23.7%)
-
Fatigue (19.9%)
-
Headache (18%)
-
Myalgia (17.6%)
Side Effect
Description, lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor in
Side Effect
Description, lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor in
Vimkunya® Resources
No posts found for selected source: resource
Find out more
02 July 2025
VIMKUNYA™ is an FDA- and EMA-approved, single-dose, recombinant chikungunya vaccine for individuals 12+ years, demonstrating high immunogenicity and tolerability. It’s stored refrigerated, shaken before use, and administered IM. Most adverse effects are mild and transient, with rare serious events that require standard post-vaccination monitoring.